CliffBio
small molecule

BELSOMRA

SUVOREXANT

Loss of exclusivityMay 2033latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME CORP

Drug detail

Brand nameBELSOMRA
Active ingredientSUVOREXANT
Strength20MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2014
Marketing statusRX

Listed patents

PatentExpiresType
11980623May 2033product
10098892May 2033product
7951797November 2029substance, product

More from MERCK SHARP AND DOHME CORP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BELSOMRA patent cliff — loss of exclusivity May 2033 | CliffBio